Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196，HKG: 2196), a Chinese pharmaceutical heavyweight, has entered...
HKG: 2196
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...
Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment
Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...
Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial
Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...
Shanghai Henlius Biotech Submits Another Application for Serplulimab in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...
Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District
Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event...
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...
Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...
Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...
Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...
Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization
China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co.,...
Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study
Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...
Kexing Pharmaceutical Secures Commercial Rights for Convalife’s Neratinib Generic Outside China
China-based Kexing Pharmaceutical (SHA: 688136) has announced a licensing agreement with compatriot firm Convalife, securing...
Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...